However, the BMJ hasn't yet put these messages on its cover. Contentious papers are more newsworthy.
I thank Lee Hooper, Davey Smith and Shah Ebrahim for courteous and reasoned comments on my review of two reviews they published on dietary fat and cardiovascular disease (CVD) and on advice to reduce salt intake and blood pressure. Their letter makes the usual excellent points that randomization is an ideal and that observational studies can be greatly weakened by all sorts of confounding.
My paper was presented, with some trepidation, at an international session attended by some of the leaders of the Cochrane collaboration, because I believe I was expressing views of a number of nutrition scientists who advise on food and nutrition policy.
Cochrane reviews were designed to assess the value of treatments as objectively as possible. They are at their best with pharmaceutical drug trials. In weighing up all the evidence for nutritional advice, however, Cochrane reviews are only, can only be one of the inputs. Cochrane reviews can have their problems, as can observational epidemiology and other nutrition research. These are more likely with nutritional trials than with drug trials.
In their letter Hooper et al. have not mentioned several problems I raised about their review of dietary fat and CVD. They have not justified including strokes with coronary heart disease in the same analysis or lumping total fat reduction with reduced saturated plus decreased polyunsaturated fat. They are different dietary treatments and reducing total fat is unlikely to be effective (Howard et al., 2006) .
It was a mistake to use the US National Diet Heart Study (1968) as a trial (that provided 10 of the 42 lines in their Table 1 ) when its authors carefully wrote that it was a feasibility study, not a trial to assess effect of diet on disease itself. Selection of the trials of the disease outcomes and of the dietary changes are all important, like randomization.
In their review of long-term effects of advice to reduce dietary salt the main problem, I think, that salt experts (and I) found was more with the writing, the interpretation alongside the rigorous meta-analysis. Their discussion quotes a small number of papers and gives prominence to the possibility that lowering sodium intake may have adverse effects on serum cholesterol (not seen in ecological studies) and has been associated with more CVD. This quotes a paper that has been shown to be flawed (McGregor and de Wardener, 1998) . These discouraging comments were not based on a critical review of the literature. 'Intensive interventions, unsuited to primary care' y are mentioned but it is not clear why they are unsuited or how many of the trials were of this type. Beard (2004) has a cohort of enthusiastic 'salt skippers' who manage to keep their urinary sodium down by careful choice of their foods. Simply to put away the salt shaker is not enough. WPT James et al. (1987) showed nearly 20 years ago in Scotland that most of the salt we eat is put in at the food factory.
However, the biggest problem with their salt review was the way the BMJ blew up its discouraging commentary with a colour picture of salt works on the cover and the subeditor's interpretation in large letters: 'Salt reduction in individuals. Hard to achieve, harder to sustain, and maybe not worth the effort'.
Wisely the UK Scientific Advisory Committee on Nutrition (2003), while they cite Hooper et al. reach these conclusions, based on the broader evidence (199 papers quoted):
A reduction in the average population salt intake would proportionally lower blood pressure levels and confer significant public health benefits by contributing to decrease in the burden of cardiovascular disease y A substantial reduction in the current average salt intake of the population is required. This would be best achieved using a population-based approach y. A reduction in the salt content of processed food and drink is necessary y 
